• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    6/30/22 6:00:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email
    • All matters approved by shareholders

    • Two new directors elected to the board

    TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results from the Company's 2022 Annual and Special Shareholders' Meeting (the "Meeting") held on June 29, 2022, in Toronto, Ontario. At the Meeting, shareholders elected new members to the board of directors, among other matters approved.

    Mark Brennan, Executive Chairman, commented, "We are very pleased with the outcome of the Meeting and welcome Bob Sellers and Chris Jones to the Ascendant Board. They each bring a wealth of knowledge and experience in the corporate and capital market areas that will provide strong support to Ascendant's continued corporate growth and the development of Lagoa Salgada." He continued, "We would like to thank Ms. Petra Decher for her significant contributions to the Company during her tenure at Ascendant and wish her well with her current commitments."

    Robert (Bob) M. Sellars has 40 years experience in capital markets and financial services and has significant experience on investment industry committees within the IIROC. Mr. Sellars holds the position of Chief Financial Officer at Red Cloud Financial Services Inc. Previously, Mr. Sellars served as Chief Financial Officer & Executive Vice President for Dundee Corp. Mr. Sellars is a Chartered Professional Accountant (CPA), Chartered Accountant (CA), Chartered Financial Analyst (CFA) and received an MBA from the University of Windsor.

    Christopher Jones is a Chartered Professional Accountant (CPA), Chartered Accountant (CA), Licensed Public Accountant (LPA), Chartered Financial Analyst (CFA) and Chartered Business Valuator (CBV). As the youngest Partner at Williams & Partners; Chartered Accountants, he advises on complex taxation strategies, growth strategies, cash flow management, financing strategies, wealth management, and succession planning. Chris advises several private equity firms on acquisition targets and appropriate due diligence requirements highlighting key risk areas and maximizing target potential while serving as an advisor to high-net worth clients and families.

    A total of 24,161,561 common shares were voted at the Meeting, representing 19% of the votes attached to all outstanding common shares of the Company. All matters presented for shareholder approval at the Meeting were duly authorized and approved as follows:

    Number of Directors to be Elected

    On a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at seven (7) was approved. The following favourable votes were cast by proxy:

     Total Votes% of Votes Cast
    Votes in Favour

    Votes Against
    23,075,764

    536,068
    97.73%

    2.27%
    Total Votes Cast23,611,832100%



    Election of Directors

    The shareholders elected each of the six nominees listed in the Company's Management Proxy Circular. Details of the voting results are as follows:

    NameVotes in Favour%Votes Withheld%
    Mark Brennan22,845,27096.75%766,5623.25%
    Robert Campbell23,075,76497.73%536,0682.27%
    Christopher Jones23,079,17097.74%532,6622.26%
    Kurt Menchen23,075,76497.73%536,0682.27%
    Rui Botica Santos23,075,76497.73%536,0682.27%
    Robert Sellars23,079,17097.74%532,6622.26%
    Stephen Shefsky23,075,76497.73%536,0682.27%



    Appointment of Auditors

    KPMG LLP was appointed auditor of the Corporation and the directors of the Corporation were authorized to fix the auditor's remuneration. Details of the voting results are as follows:

     Total Votes% of Votes Cast
    Votes in Favour23,528,94397.38%
    Votes Withheld632,6182.62%
    Total Votes Cast24,161,561100%



    Amended and Restated Omnibus Incentive Plan

    A ballot was conducted with respect to the Amended and Restated Omnibus Incentive Plan of the Corporation. According to the proxies received and ballots cast by disinterested shareholders, the resolution to approve the Amended and Restated Omnibus Incentive Plan of the Corporation was approved.

     Total Votes% of Votes Cast
    Votes in Favour22,802,86496.57%
    Votes Against808,9683.43%
    Total Votes Cast23,611,832100%



    About Ascendant Resources Inc.

    Ascendant is a Toronto-based mining company focused on the exploration and development of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. Through focused exploration and aggressive development plans, the Company aims to unlock the inherent potential of the project, maximizing value creation for shareholders.

    The Venda Nova deposit at Lagoa Salgada contains over 10.33 million tonnes of Measured and Indicated Resources @ 9.06% ZnEq and 2.50 million tonnes of Inferred Resources @ 5.93% ZnEq in the North Zone; and 4.42 million tonnes of Indicated Resources @ 1.50% CuEq and 10.83 million tonnes of Inferred resources @ 1.35% CuEq in the South Zone. The deposit demonstrates typical mineralization characteristics of Iberian Pyrite Belt VMS deposits containing zinc, copper, lead, tin, silver and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209ha property concession. The project also demonstrates compelling economics with scalability for future resource growth in the results of the Preliminary Economic Assessment. Located just 80km from Lisbon, Lagoa Salgada is easily accessible by road and surrounded by exceptional Infrastructure. Ascendant holds a 50% interest in the Lagoa Salgada project through its position in Redcorp - Empreendimentos Mineiros, Lda, ("Redcorp") and has an earn-in opportunity to increase its interest in the project to 80%. The Company's interest in the Lagoa Salgada project offers a low-cost entry to a potentially significant exploration and development opportunity, already demonstrating its mineable scale.

    The Company's common shares are principally listed on the Toronto Stock Exchange under the symbol "ASND". For more information on Ascendant, please visit our website at www.ascendantresources.com.

    For further information please contact:
      
    Mark BrennanNicholas Campbell, CFA
    Executive Chairman, FounderManager, Corporate Development
    Tel: +1-647-796-0023Tel: +1-905-630-0148
    [email protected][email protected]



    Primary Logo

    Get the next $ASND alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    7/3/2025$250.00Overweight
    Morgan Stanley
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    1/7/2025$196.00Buy
    UBS
    9/5/2024$180.00Perform → Outperform
    Oppenheimer
    6/25/2024$156.00 → $175.00Hold → Buy
    TD Cowen
    5/31/2024$200.00Buy
    Stifel
    12/20/2023$150.00Buy
    Jefferies
    More analyst ratings

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Ascendis Pharma with a new price target

    Morgan Stanley resumed coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $250.00

    7/3/25 7:49:10 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Ascendis Pharma from Equal-Weight to Overweight and set a new price target of $250.00

    5/5/25 8:26:14 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ascendis Pharma with a new price target

    RBC Capital Mkts initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $205.00

    4/16/25 9:07:14 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    SEC Filings

    View All

    SEC Form 144 filed by Ascendis Pharma A/S

    144 - Ascendis Pharma A/S (0001612042) (Subject)

    8/15/25 4:15:10 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S

    SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    8/14/25 10:57:53 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    8/13/25 4:01:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ascendis Pharma Reports Second Quarter 2025 Financial Results

    – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions  – Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning –Conference call today at 4:30 pm ET COPENH

    8/7/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

    COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascen

    7/31/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

    First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease companyOn track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA*, as well as combination therapy trials in achondroplasia and hypochondroplasia, in Q4 2025 COPENHAGEN, Denmark, July 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone

    7/28/25 7:00:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma Reports Second Quarter 2025 Financial Results

    – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions  – Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning –Conference call today at 4:30 pm ET COPENH

    8/7/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

    COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascen

    7/31/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

    - For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well to

    6/9/25 7:00:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Leadership Updates

    Live Leadership Updates

    View All

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

    COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

    1/29/24 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 1:28:32 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care